Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Efsubaglutide Alfa Injection in Subjects With Overweight or Obesity

NCT07114419 is registered in ClinicalTrials.gov with Shanghai Yinnuo Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT07114419
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07114419 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Efsubaglutide Alfa Injection in Subjects With Overweight or Obesity
Lead sponsor
Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
August 25, 2025
Completion date
August 1, 2026
Enrollment
200 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

obesity and overweight